GA-AGCO
21.5.2020 15:02:14 CEST | Business Wire | Press release
The AGCO Agriculture Foundation (AAF), a private foundation committed to ending hunger through sustainable agricultural development, today announced the launch of its COVID-19 Aid Program with a $100,000 grant to the World Food Program USA (WFP USA) in support of the United Nations World Food Programme’s (WFP) COVID-19 emergency response.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200521005211/en/
The AAF COVID-19 Aid Program’s inaugural grant to WFP USA will support the WFP, the leading humanitarian agency fighting hunger worldwide, to continue to deliver food and critical supplies at full capacity. Our donation will focus on the most vulnerable populations in Africa and Latin America.
“The urgency of hunger worldwide has become even more critical with the addition of the coronavirus, and we are directing our global support to the World Food Program USA in support of WFP’s COVID-19 relief efforts. Our funding will help monitor the impact of the pandemic, pre-position food and medical supplies in vulnerable communities in Africa and Latin America, as well as lend support to newly established supply chain coordination cells on the ground,” says Lucinda Smith, Board Chairman, AGCO Agriculture Foundation.
“We are grateful to AGCO Agriculture Foundation for their generous donation and support to raise much needed funding for WFP’s COVID-19 response efforts,” said Barron Segar, World Food Program USA President and CEO. “WFP serves as the logistics and transportation backbone to the humanitarian community and AAF’s contribution is critical to ensuring WFP can get lifesaving food and supplies to millions of the most vulnerable people.”
The AAF is matching donations up to $100,000 made at this link: www.wfpusa.org/aaf-match .
“We would like to invite our stakeholders to contribute to the World Food Program USA global emergency response to support this critical need,” said Metti Richenhagen, Managing Director, AGCO Agriculture Foundation.
“The AGCO Agriculture Foundation has launched the COVID-19 Aid Program with total funding of $500,000 and is also making grants to local non-profit organizations focused on the prevention and relief of hunger in the communities where we live and work across the globe.”
About the AGCO Agriculture Foundation (AAF)
The AGCO Agriculture Foundation (AAF) , initiated by AGCO Corporation (NYSE: AGCO) in 2018, is a private foundation with the vision to prevent and relieve hunger. The foundation initiates impactful programs that support food security, foster sustainable agricultural development and build needed agricultural infrastructure in marginalized farming communities. AAF is domiciled in Vaduz, Liechtenstein and operations are managed from Duluth, Georgia, USA. For more information, please visit https://www.agcocorp.com/commitment/sustainability/focus-areas/communities.html .
About World Food Program USA
World Food Program USA is the recognized leader in America’s pursuit to end global hunger, inspiring citizens to do everything in their power to create a zero-hunger world. WFP USA works with U.S. policymakers, corporations, foundations and individuals to generate financial and in-kind resources for the United Nations World Food Programme to feed families in need around the world and to develop policies necessary to alleviate global hunger. To learn more about WFP USA’s mission, please visit us at www.wfpusa.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200521005211/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 09:00:00 CET | Press release
Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi
Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 07:00:00 CET | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare
HJS Foundation Releases JEP Protocol & HJS Framework: The "Black Box" for AI, Enabling Verifiable Human Oversight24.3.2026 04:36:00 CET | Press release
HJS Foundation (Human Judgment Systems Foundation) today released two complementary solutions: the Judgment Event Protocol (JEP) and the Human Judgment Structure (HJS) framework. As a minimalist open standard, JEP generates tamper-proof records of AI decision accountability, just like an aircraft black box; HJS embeds human judgment logic into AI operation processes — together, they transform "human oversight" from a regulatory requirement into a verifiable technical fact, providing an optional technical solution for AI accountability. How to prove that AI decisions (such as loan approvals, medical diagnoses, border screenings, etc.) have undergone human review? JEP generates immutable audit trails of human intervention through four cryptographic primitives — Judge, Verify, Delegate, Terminate; HJS builds a controllable and accountable system to prevent risks such as AI drift and ensure that human judgment guides AI operations. Current systems rely on alterable post-hoc documentation,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom